The phage therapy paradigm: prêt-à-porter or sur-mesure?
Jean-Paul Pirnay, Daniel De Vos, Gilbert Verbeken, Maia Merabishvili, Nina Chanishvili, Mario Vaneechoutte, Martin Zizi, Geert Laire, Rob Lavigne, Isabelle Huys, Guy Van den Mooter, Angus Buckling, Laurent Debarbieux, Flavie Pouillot, Joana Azeredo, Elisabeth Kutter, Alain Dublanchet, Andrzej Górski, Revaz Adamia
Author Information
- Jean-Paul Pirnay: Laboratory for Molecular and Cellular Technology, Burn Wound Centre, Queen Astrid Military Hospital, 1120, Brussels, Belgium.
No abstract text available.
- Nat Rev Microbiol. 2004 Feb;2(2):166-73
[PMID: 15040264]
- Vaccine. 2003 May 1;21(16):1786-8
[PMID: 12686095]
- Future Microbiol. 2007 Oct;2(5):485-91
[PMID: 17927471]
- Trends Parasitol. 2010 Feb;26(2):83-92
[PMID: 20036799]
- Curr Opin Investig Drugs. 2009 Aug;10(8):766-74
[PMID: 19649921]
- Proc Biol Sci. 2002 May 7;269(1494):931-6
[PMID: 12028776]
- Nat Biotechnol. 2004 Jan;22(1):31-6
[PMID: 14704699]
- Antimicrob Agents Chemother. 2001 Mar;45(3):649-59
[PMID: 11181338]
- Curr Pharm Biotechnol. 2010 Jan;11(1):69-86
[PMID: 20214609]
- PLoS One. 2009;4(3):e4944
[PMID: 19300511]
Anti-Bacterial Agents
Bacterial Infections
Bacteriophages
Drug Industry
Humans
